サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1286729

自動注射器の世界市場：用途別 (再利用型、使い捨て型)・技術別 (手動式、自動式)・治療領域別 (関節リウマチ、糖尿病、アナフィラキシー)・投与経路別 (皮下 (SC)、筋肉内 (IM))・容量別 (3ml未満、3ml超)・エンドユーザー別 (在宅医療、病院) の将来予測 (2028年まで)

Autoinjectors Market by Usage (Reusable, Disposable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Anaphylaxis), Route of administration (SC, IM), Volume (<3ml, >3ml), End User (Home Care, Hospitals) - Global Forecast to 2028
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 312 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
自動注射器の世界市場：用途別 (再利用型、使い捨て型)・技術別 (手動式、自動式)・治療領域別 (関節リウマチ、糖尿病、アナフィラキシー)・投与経路別 (皮下 (SC)、筋肉内 (IM))・容量別 (3ml未満、3ml超)・エンドユーザー別 (在宅医療、病院) の将来予測 (2028年まで)
出版日: 2023年06月02日
発行: MarketsandMarkets
ページ情報: 英文 312 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の自動注射器の市場規模は、2023年の9億米ドルから2028年には17億米ドルに達し、14.0%のCAGRで成長すると予測されています。

一方、自動注射器向け最終製剤の市場規模は、2023年の596億米ドルから、2028年には1,365億米ドルに達し、18.0%のCAGRで成長すると予測されています。自動注射器市場の成長を促進する主な要因は、自動注射器のジェネリックバージョンの利用可能性が高まっていること、救急医療において自動注射器の利点などが挙げられます。他方、経口・経鼻・局所といった代替的な薬剤送達モードが、市場の成長をある程度抑制すると予想されます。

"技術別では、手動式自動注射器の分野が最大のシェアを占める"

手動式自動注射器のセグメントは、その利点のゆえに、2022年に市場を独占しました。主な利点として、患者のコントロールの向上、使いやすさ、安全性と精度の向上などがあります。手動式自動注射器は、患者や介護者が準備ができたときにだけ薬を投与することができます。これにより、より安全で正確な投薬が可能になります。

"エンドユーザー別では、在宅医療のセグメントが最大のシェアを占める"

2022年に自動注射器市場で最大のシェアを占めたのは、在宅医療のセグメントでした。この市場セグメントの成長は、病院での治療よりも在宅医療の方が比較的低コストなこと、自動注射器を用いた薬剤の自己投与が容易であることに起因すると考えられます。

"北米：自己注射器市場の最大シェア"

地域別では、北米が最大のシェアを占めています。北米地域の大きなシェアは、薬の自己投与に対する高い認識と導入に起因していると考えられます。さらに、自動注射器に対する有利な償還制度が市場の成長に寄与しています。米国やカナダなどの先進諸国では、薬剤の自己投与に対する意識が高く、その結果、薬剤の自己投与が普及していることが確認されています。これは、同地域の政府、保険会社などが提供する有利な償還金によって支えられています。

"アジア太平洋：自動注射器市場において最も成長著しい地域"

アジア太平洋の自動注射器市場は、予測期間中に最も高いCAGRで成長すると予測されています。この背景には、ジェネリック医薬品を提供する製薬・バイオ医薬品業界の継続的な成長と、同地域で自動注射器製品の承認数が増加していることがあります。また、この地域は高齢者人口が多く、糖尿病や心血管疾患などの慢性疾患の有病率も高いです。そのため、投薬の頻度が高いことから、投薬の自己投与の採用が増加すると予想されます。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 主要な業界動向
  • 顧客のビジネスに影響を与える動向/混乱
  • 価格分析
  • バリューチェーン分析
  • サプライチェーン分析
  • エコシステム分析
  • テクノロジー分析
  • 特許分析
  • 主な会議とイベント (2023年～2024年)
  • 貿易データ
  • 規制分析
  • ポーターのファイブフォース分析
  • 主要な利害関係者と購入基準

第6章 自動注射器市場：用途別

  • イントロダクション
  • 使い捨て型自動注射器
  • 再利用型自動注射器

第7章 自動注射器市場：技術別

  • イントロダクション
  • 手動式自動注射器
  • 自動式自動注射器

第8章 自動注射器市場：投与経路別

  • イントロダクション
  • 皮下 (SC)
  • 筋肉内 (IM)

第9章 自動注射器市場：治療領域別

  • イントロダクション
  • 関節リウマチ
  • 糖尿病
  • 多発性硬化症
    • アナフィラキシー
    • その他の治療領域

第10章 自動注射器市場：容量別

  • イントロダクション
  • 容量3ml未満
  • 容量3ml超 (大容量)

第11章 自動注射器市場：エンドユーザー別

  • イントロダクション
  • 在宅医療
  • 病院・診療所
  • 外来診療

第12章 自動注射器市場：地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • その他のアジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第13章 競合情勢

  • イントロダクション
  • 主要企業が採用した戦略
  • 収益シェア分析：自動注射器市場
  • 収益シェア分析：自動注射器向け最終製剤市場
  • 市場シェア分析：自動注射器市場
  • 市場シェア分析：自動注射器向け最終製剤市場
  • 企業評価マトリックス：主要企業
  • 競合ベンチマーキング：上位25社
  • 企業評価マトリックス：スタートアップ/中小企業
  • 競合ベンチマーキング：スタートアップ/中小企業
  • 競合シナリオと動向

第14章 企業プロファイル

  • 主要企業：装置
    • BECTON, DICKINSON AND COMPANY (BD)
    • YPSOMED HOLDING AG
    • SHL MEDICAL
    • WEST PHARMACEUTICAL SERVICES, INC.
    • RECIPHARM AB
    • HASELMEIER GMBH
    • OWEN MUMFORD LTD.
    • GERRESHEIMER AG
    • PHILLIPS-MEDISIZE, LLC
    • OVAL MEDICAL TECHNOLOGIES LTD. (PART OF SMC LTD.)
    • KALEO, INC.
    • SOLTEAM INCORPORATION CO., LTD.
    • ELCAM DRUG DELIVERY DEVICES (E3D)
    • CROSSJECT
    • JOHNSON MEDTECH, LLC. (PART OF JOHNSON ELECTRIC HOLDINGS LTD.)
    • ANTARES PHARMA, INC. (PART OF HALOZYME, INC.)
    • JABIL, INC.
    • CONGRUENCE MEDICAL SOLUTIONS LLC
  • 主要企業：最終製剤
    • ABBVIE INC.
    • AMGEN INC.
    • ELI LILLY AND COMPANY
    • NOVARTIS AG
    • MERCK KGAA
    • VIATRIS INC. (FORMERLY MYLAN INC.)
    • BIOGEN

第15章 付録

目次
Product Code: MD 6494

The global autoinjector devices market is projected to reach USD 1.7 billion in 2028 from USD 0.9 billion in 2023, growing at a CAGR of 14.0%. Where as, the autoinjector finished formulations market is projected to reach USD 136.5 billion in 2028 from USD 59.6 billion in 2023, growing a CAGR of 18.0%. The key factors driving the growth of the autoinjectors market are the increasing availability of generic versions of autoinjectors and advantages offered by autoinjectors in emergency medical care is expected to propel the growth of the market. However, alternative modes of drug delivery such as oral, nasal, and topical among others are expected to restrain market growth to a certain extent.

The autoinjectors market has been segmented based on technology, usage, route of administration, volume, therapy area, end user and region.

"By technology, the manual autoinjectors segment accounted for the largest share of the autoinjectors market"

Based on technology, the autoinjectors market is categorized into manual, and automatic. The manual autoinjectors segment dominated the market in 2022, owing to the advantages that they offer. These include greater patient control, ease of use, improved safety and accuracy among others. Manual autoinjectors allow patinets and caregivers to administer the medication only when they are ready. This allows for more safe and accurate administration of medication dose.

"By end user, the home care settings segment accounted for the largest share in the autoinjectors market"

Based on end user, the autoinjectors market is segmented into home care settings, hospitals and clinics, and ambulatory care settings. In 2022, the home care settings segment accounted for a largest share of the autoinjectors market. Growth in this market segment can be attributed to relatively lower costs incurred for home care therapies than for treatments in hospitals and the ease of self-administration of drugs using autoinjectors.

"North America: the largest share of the autoinjectors market"

North America accounted for the largest share of the autoinjectors market. The large share of the North America region can be attributed to high awareness and adoption of self-administration of medication. Moreover, favorable reimbursements for autoinjectors has contributed to the growth of the market. Developed countries like the US and Canada have been observed to havehigher awareness and thus, adoption of self-administration drug delivery. This is supported by the favorable reimbursements offered by the government, insurance entities among others in the region.

"Asia Pacific: The fastest-growing region in the autoinjectors market."

The Asia Pacific autoinjectors market is projected to grow at the highest CAGR during the forecast period. This is attributed to the continuously growing pharmaceutical and biopharmaceutical industries offering generic versions of autoinjectors and growing number of approvals for autoinjector products in the region. Besides, the region has presence of large number of geratric population and a high prevalence of chronic disease including diabetes and cardiovascular diseases. Therefore, the adoption of self-administration of medication is expected to increasing owing to the high frequency of these medications.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: Managers - 45%, Directors- 30%, and Executives - 25%
  • By Country: North America- 40%, Europe- 25%, Asia Pacific- 20%, Latin America- 10%, and Middle East & Africa- 5%

Prominent Players

  • Becton, Dickinson and Company (BD) (US)
  • Ypsomed Holding AG (Switzerland)
  • sSHL Medical (Switzerland)
  • West Pharmaceutical Services, Inc. (US)
  • Recipharm AB (Sweden)
  • Haselmeier GmbH (Germany)
  • Owen Mumford Ltd. (UK)
  • Gerresheimer AG (Germany)
  • Phillips-Medisize, LLC (US)
  • Oval Medical Technologies Ltd. (UK)
  • Kaleo, Inc. (US), Solteam Incorporation Co., Ltd. (China)
  • Elcam Drug Delivery Devices (E3D) (Israel)
  • Crossject (France)
  • Johnson MedTech, LLC. (US), Antares Pharma, Inc. (US)
  • Jabil, Inc. (US)
  • Congruence Medical Solutions LLC (US)
  • AbbVie Inc. (US)
  • Amgen Inc. (US)
  • Eli Lilly and Company (US)
  • Novartis AG (Switzerland)
  • Merck KGaA (Germany)
  • Viatris Inc. (US)
  • Biogen (US)

Research Coverage:

This report provides a detailed picture of the autoinjectors market. It aims at estimating the size and future growth potential of the market across different segments, such as the usage (reusable and disposable), technology (manual and automatic), route of administration (intramuscular and subcutaneous), therapy area (rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, and other therapy areas), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall autoinjectors market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

The report provide insights on the following pointers"

  • Analysis of key drivers (the benefits of autoinjectors in emergency medical care, growth in the number of regulatory approvals, availability of generic versions of autoinjectors, government support and favorable reimbursements, and the growing adoption of self-administration), restraints (alternative drug delivery modes and needle phobia), opportunities (patent expiry of biologics and the increasing shift of therapy to home settings), and challenges (development of autoinjectors for multiple drug viscosities) influencing the growth of the autoinjectors market.
  • Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the autoinjectors market.
  • Market Development: Comprehensive information about lucrative markets- the report analyses the autoinjectors market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the autoinjectors market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Becton, Dickinson and Company (BD), Ypsomed Holding AG, SHL Medical among others in the autoinjectors devices market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • FIGURE 1 AUTOINJECTORS MARKET SEGMENTATION
    • 1.3.1 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES
    • 1.7.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 AUTOINJECTORS MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION OF AUTOINJECTOR DEVICES
    • FIGURE 4 MARKET SIZE ESTIMATION: AUTOINJECTOR DEVICES
    • FIGURE 5 AUTOINJECTORS MARKET SIZE ESTIMATION: OVERALL APPROACH
    • FIGURE 6 MARKET SIZE ESTIMATION FOR AUTOINJECTOR DEVICES: APPROACH 1 (REVENUE SHARE ANALYSIS)
  • 2.3 MARKET SIZE ESTIMATION OF AUTOINJECTOR FINISHED FORMULATIONS
    • FIGURE 7 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
    • FIGURE 8 MARKET SIZE ESTIMATION FOR AUTOINJECTOR FINISHED FORMULATIONS: APPROACH 1 (REVENUE SHARE ANALYSIS)
    • 2.3.1 INSIGHTS FROM PRIMARIES
    • FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS
    • FIGURE 10 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.4 GROWTH FORECAST
    • FIGURE 11 AUTOINJECTOR DEVICES MARKET: CAGR PROJECTIONS
    • FIGURE 12 AUTOINJECTOR FINISHED FORMULATIONS MARKET: CAGR PROJECTIONS
    • FIGURE 13 AUTOINJECTORS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 14 DATA TRIANGULATION METHODOLOGY
  • 2.6 RESEARCH ASSUMPTIONS
  • 2.7 RISK ANALYSIS
  • 2.8 IMPACT OF RECESSION ON AUTOINJECTORS MARKET
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)

3 EXECUTIVE SUMMARY

    • FIGURE 15 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 16 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2023 VS. 2028 (USD BILLION)
    • FIGURE 17 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 18 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD BILLION)
    • FIGURE 19 AUTOINJECTOR DEVICES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 20 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
    • FIGURE 21 GEOGRAPHICAL SNAPSHOT: AUTOINJECTOR DEVICES MARKET
    • FIGURE 22 GEOGRAPHICAL SNAPSHOT: AUTOINJECTOR FINISHED FORMULATIONS MARKET

4 PREMIUM INSIGHTS

  • 4.1 AUTOINJECTOR FINISHED FORMULATIONS AND DEVICES MARKET OVERVIEW
    • FIGURE 23 INCREASING NUMBER OF REGULATORY APPROVALS TO DRIVE MARKET GROWTH
  • 4.2 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET SHARE, BY USAGE AND COUNTRY (2022)
    • FIGURE 24 DISPOSABLE AUTOINJECTORS SEGMENT DOMINATED NORTH AMERICAN AUTOINJECTOR DEVICES MARKET IN 2022
  • 4.3 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET SHARE, BY ROUTE OF ADMINISTRATION AND COUNTRY (2022)
    • FIGURE 25 SUBCUTANEOUS ROUTE OF ADMINISTRATION SEGMENT DOMINATED NORTH AMERICAN AUTOINJECTOR FINISHED FORMULATIONS MARKET IN 2022
  • 4.4 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2023 VS. 2028 (USD MILLION)
    • FIGURE 26 RHEUMATOID ARTHRITIS SEGMENT TO CONTINUE TO DOMINATE MARKET BY 2028
  • 4.5 OVERALL AUTOINJECTORS MARKET SHARE, BY TECHNOLOGY, 2022
    • FIGURE 27 MANUAL AUTOINJECTORS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
  • 4.6 AUTOINJECTOR DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 28 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN AUTOINJECTOR DEVICES MARKET FROM 2023 TO 2028
  • 4.7 AUTOINJECTOR FINISHED FORMULATIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 29 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN AUTOINJECTOR FINISHED FORMULATIONS MARKET FROM 2023 TO 2028

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 30 AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 2 AUTOINJECTORS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Benefits of autoinjectors in emergency medical care
      • 5.2.1.2 Increasing regulatory approvals for autoinjectors
    • TABLE 3 RECENT APPROVALS OF AUTOINJECTOR BIOLOGICS IN US AND EUROPE
      • 5.2.1.3 Availability of generics and biosimilars in autoinjectors
      • 5.2.1.4 Government support and favorable reimbursements
      • 5.2.1.5 Growing awareness and adoption of self-administration
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Alternative drug delivery modes and needle phobia
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Patent expiry of biologics
    • TABLE 4 PATENT EXPIRY OF KEY BIOLOGICS
      • 5.2.3.2 Increasing shift of therapy to home settings
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Development of autoinjectors for multiple drug viscosities
  • 5.3 KEY INDUSTRY TRENDS
    • 5.3.1 INCREASING ADOPTION OF WEARABLE AUTOINJECTORS
    • 5.3.2 DEVELOPMENT AND LAUNCH OF ENVIRONMENT-FRIENDLY AUTOINJECTORS
  • 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 31 REVENUE SHIFT AND NEW REVENUE POCKETS FOR AUTOINJECTOR PROVIDERS
  • 5.5 PRICING ANALYSIS
    • TABLE 5 AVERAGE SELLING PRICE OF EPINEPHRINE AUTOINJECTORS, BY REGION, 2015 VS. 2020
    • TABLE 6 INDICATIVE PRICING ANALYSIS OF AUTOINJECTOR FINISHED FORMULATIONS
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 32 AUTOINJECTORS MARKET: VALUE CHAIN ANALYSIS
  • 5.7 SUPPLY CHAIN ANALYSIS
    • FIGURE 33 AUTOINJECTORS MARKET: SUPPLY CHAIN ANALYSIS
    • TABLE 7 OVERALL SUPPLY CHAIN ECOSYSTEM FOR AUTOINJECTORS
  • 5.8 ECOSYSTEM ANALYSIS
    • FIGURE 34 ECOSYSTEM ANALYSIS: AUTOINJECTORS MARKET
  • 5.9 TECHNOLOGY ANALYSIS
  • 5.10 PATENT ANALYSIS
    • FIGURE 35 PATENT APPLICATIONS FOR AUTOINJECTORS, JANUARY 2012-APRIL 2023
    • TABLE 8 INDICATIVE LIST OF PATENTS IN AUTOINJECTORS MARKET
  • 5.11 KEY CONFERENCES AND EVENTS IN 2023-2024
    • TABLE 9 AUTOINJECTORS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
  • 5.12 TRADE DATA
    • TABLE 10 IMPORT AND EXPORT DATA FOR PRODUCTS INCLUDING AUTOINJECTORS, AMONG OTHERS, 2022
  • 5.13 REGULATORY ANALYSIS
    • 5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.14 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 15 AUTOINJECTORS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.14.1 THREAT OF NEW ENTRANTS
    • 5.14.2 THREAT OF SUBSTITUTES
    • 5.14.3 BARGAINING POWER OF SUPPLIERS
    • 5.14.4 BARGAINING POWER OF BUYERS
    • 5.14.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AUTOINJECTOR DEVICES
    • 5.15.2 BUYING CRITERIA FOR AUTOINJECTOR DEVICES
    • FIGURE 37 KEY BUYING CRITERIA FOR END USERS

6 AUTOINJECTORS MARKET, BY USAGE

  • 6.1 INTRODUCTION
    • TABLE 16 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 17 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (MILLION UNITS)
    • TABLE 18 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
  • 6.2 DISPOSABLE AUTOINJECTORS
    • 6.2.1 CONVENIENCE OF USE FOR PATIENTS TO DRIVE GROWTH
    • TABLE 19 DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 20 DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021-2028 (MILLION UNITS)
    • TABLE 21 NORTH AMERICA: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 22 EUROPE: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 23 ASIA PACIFIC: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 24 DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 25 NORTH AMERICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 26 EUROPE: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 27 ASIA PACIFIC: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 REUSABLE AUTOINJECTORS
    • 6.3.1 REUSABLE AUTOINJECTORS TO ACCOUNT FOR LOWER SHARE OF MARKET
    • TABLE 28 REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 29 REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2021-2028 (MILLION UNITS)
    • TABLE 30 NORTH AMERICA: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 31 EUROPE: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 32 ASIA PACIFIC: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 33 REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 34 NORTH AMERICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 35 EUROPE: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 36 ASIA PACIFIC: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

7 AUTOINJECTORS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 37 AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 38 AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (MILLION UNITS)
    • TABLE 39 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • 7.2 MANUAL AUTOINJECTORS
    • 7.2.1 MANUAL AUTOINJECTORS SEGMENT TO ACCOUNT FOR LARGER MARKET SHARE DURING FORECAST PERIOD
    • TABLE 40 MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 41 MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2021-2028 (MILLION UNITS)
    • TABLE 42 NORTH AMERICA: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 43 EUROPE: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 44 ASIA PACIFIC: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 45 MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 46 NORTH AMERICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 47 EUROPE: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 48 ASIA PACIFIC: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 AUTOMATIC AUTOINJECTORS
    • 7.3.1 AUTOMATIC AUTOINJECTORS INTEGRATE ELECTRONIC COMPONENTS AND ADDITIONAL FEATURES TO ENHANCE INJECTION PROCESS
    • TABLE 49 AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 50 AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2021-2028 (MILLION UNITS)
    • TABLE 51 NORTH AMERICA: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 52 EUROPE: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 54 AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 55 NORTH AMERICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 56 EUROPE: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 57 ASIA PACIFIC: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

8 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION

  • 8.1 INTRODUCTION
    • TABLE 58 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 59 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (MILLION UNITS)
  • 8.2 SUBCUTANEOUS
    • 8.2.1 INCREASING NUMBER OF PRODUCT APPROVALS TO DRIVE GROWTH
    • TABLE 60 AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 61 SUBCUTANEOUS AUTOINJECTOR DEVICES MARKET, BY REGION, 2021-2028 (MILLION UNITS)
    • TABLE 62 NORTH AMERICA: AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 63 EUROPE: AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 64 ASIA PACIFIC: AUTOINJECTORS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 INTRAMUSCULAR
    • 8.3.1 INTRAMUSCULAR ROUTE OF ADMINISTRATION ENABLES FASTER ABSORPTION OF MEDICATION
    • TABLE 65 AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 66 INTRAMUSCULAR AUTOINJECTOR DEVICES MARKET, BY REGION, 2021-2028 (MILLION UNITS)
    • TABLE 67 NORTH AMERICA: AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 68 EUROPE: AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 69 ASIA PACIFIC: AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)

9 AUTOINJECTORS MARKET, BY THERAPY AREA

  • 9.1 INTRODUCTION
    • TABLE 70 AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 71 AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (MILLION UNITS)
    • TABLE 72 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
  • 9.2 RHEUMATOID ARTHRITIS
    • 9.2.1 BENEFITS OF AUTOINJECTORS IN RHEUMATOID ARTHRITIS TREATMENT TO PROPEL GROWTH
    • TABLE 73 AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 74 AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021-2028 (MILLION UNITS)
    • TABLE 75 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 76 EUROPE: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 77 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 78 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 79 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 80 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 81 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 DIABETES
    • 9.3.1 LARGE DIABETIC POPULATION TO DRIVE DEMAND FOR AUTOINJECTORS
    • FIGURE 38 DIABETIC POPULATION: TOP COUNTRIES/TERRITORIES (20-79 YEARS), 2019 VS. 2030 VS. 2045
    • TABLE 82 AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 83 AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION, 2021-2028 (MILLION UNITS)
    • TABLE 84 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 85 EUROPE: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 86 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 87 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 88 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 89 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 90 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.4 MULTIPLE SCLEROSIS
    • 9.4.1 AVAILABILITY OF ORAL GENERIC MEDICINES TO NEGATIVELY IMPACT GROWTH
    • TABLE 91 AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 92 AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021-2028 (MILLION UNITS)
    • TABLE 93 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 94 EUROPE: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 95 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 96 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 97 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 98 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 99 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 9.4.2 ANAPHYLAXIS
      • 9.4.2.1 Increasing prevalence of food allergies to drive growth
    • TABLE 100 AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 101 AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION, 2021-2028 (MILLION UNITS)
    • TABLE 102 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 103 EUROPE: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 104 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 105 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 106 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 107 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 108 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 9.4.3 OTHER THERAPY AREAS
    • TABLE 109 AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 110 AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021-2028 (MILLION UNITS)
    • TABLE 111 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 112 EUROPE: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 113 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 114 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 115 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 116 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 117 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2021-2028 (USD MILLION)

10 AUTOINJECTORS MARKET, BY VOLUME

  • 10.1 INTRODUCTION
    • TABLE 118 AUTOINJECTORS MARKET, BY VOLUME, 2021-2028 (USD MILLION)
    • TABLE 119 AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021-2028 (MILLION UNITS)
  • 10.2 UP TO 3 ML VOLUME
    • 10.2.1 INCREASING USE OF SUBCUTANEOUS INJECTIONS AGAINST CHRONIC DISEASES TO DRIVE GROWTH
    • TABLE 120 UP TO 3 ML VOLUME AUTOINJECTORS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 121 UP TO 3 ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2021-2028 (MILLION UNITS)
  • 10.3 ABOVE 3 ML VOLUME (LARGE VOLUME)
    • 10.3.1 GROWING RESEARCH TO STUDY POTENTIAL OF LARGE-VOLUME AUTOINJECTORS TO DRIVE GROWTH
    • TABLE 122 ABOVE 3 ML VOLUME AUTOINJECTORS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 123 ABOVE 3 ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2021-2028 (MILLION UNITS)

11 AUTOINJECTORS MARKET, BY END USER

  • 11.1 INTRODUCTION
    • TABLE 124 AUTOINJECTORS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.2 HOME CARE SETTINGS
    • 11.2.1 COST-EFFECTIVENESS OF HOME CARE THERAPIES TO PROPEL GROWTH
    • TABLE 125 AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 126 NORTH AMERICA: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 127 EUROPE: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 128 ASIA PACIFIC: AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.3 HOSPITALS AND CLINICS
    • 11.3.1 USE OF AUTOINJECTORS IN EMERGENCY CASES IN HOSPITALS AND CLINICS TO DRIVE GROWTH
    • TABLE 129 AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 130 NORTH AMERICA: AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 131 EUROPE: AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 132 ASIA PACIFIC: AUTOINJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.4 AMBULATORY CARE SETTINGS
    • 11.4.1 INCREASING PATIENT VOLUME IN AMBULATORY CARE SETTINGS TO DRIVE GROWTH
    • TABLE 133 AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 134 NORTH AMERICA: AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 135 EUROPE: AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 136 ASIA PACIFIC: AUTOINJECTORS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)

12 AUTOINJECTORS MARKET, BY REGION

  • 12.1 INTRODUCTION
    • TABLE 137 AUTOINJECTOR DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 138 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 12.2 NORTH AMERICA
    • FIGURE 39 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET SNAPSHOT
    • TABLE 139 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 140 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 141 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 142 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 143 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 144 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021-2028 (USD MILLION)
    • TABLE 145 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 146 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 147 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 148 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 149 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 150 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 151 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021-2028 (USD MILLION)
    • TABLE 152 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.2.1 US
      • 12.2.1.1 US to dominate North American market during forecast period
    • TABLE 153 AUTOINJECTORS APPROVED BY US FDA, 2022
    • TABLE 154 US: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 155 US: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 156 US: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 157 US: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 158 US: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 159 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 160 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 161 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 162 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 163 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.2.2 CANADA
      • 12.2.2.1 Rising prevalence of chronic diseases to drive growth
    • TABLE 164 CANADA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 165 CANADA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 166 CANADA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 167 CANADA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 168 CANADA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 169 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 170 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 171 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 172 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 173 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.2.3 NORTH AMERICA: RECESSION IMPACT
  • 12.3 EUROPE
    • TABLE 174 EUROPE: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 175 EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 176 EUROPE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 177 EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 178 EUROPE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 179 EUROPE: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021-2028 (USD MILLION)
    • TABLE 180 EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 181 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 182 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 183 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 184 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 185 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 186 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021-2028 (USD MILLION)
    • TABLE 187 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.1 GERMANY
      • 12.3.1.1 Growing government support to propel market
    • TABLE 188 GERMANY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 189 GERMANY: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 190 GERMANY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 191 GERMANY: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 192 GERMANY: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 193 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 194 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 195 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 196 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 197 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.2 UK
      • 12.3.2.1 High prevalence of allergic conditions to boost growth
    • TABLE 198 UK: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 199 UK: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 200 UK: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 201 UK: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 202 UK: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 203 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 204 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 205 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 206 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 207 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.3 FRANCE
      • 12.3.3.1 Increasing prevalence of chronic diseases to support growth
    • TABLE 208 FRANCE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 209 FRANCE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 210 FRANCE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 211 FRANCE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 212 FRANCE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 213 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 214 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 215 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 216 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 217 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.4 ITALY
      • 12.3.4.1 Rising prevalence of chronic diseases to propel growth
    • TABLE 218 ITALY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 219 ITALY: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 220 ITALY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 221 ITALY: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 222 ITALY: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 223 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 224 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 225 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 226 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 227 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.5 SPAIN
      • 12.3.5.1 Favorable reimbursement scenario to support growth
    • TABLE 228 SPAIN: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 229 SPAIN: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 230 SPAIN: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 231 SPAIN: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 232 SPAIN: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 233 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 234 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 235 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 236 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 237 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.6 REST OF EUROPE
    • TABLE 238 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 239 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 240 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 241 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 242 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 243 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 244 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 245 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 246 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 247 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.3.7 EUROPE: RECESSION IMPACT
  • 12.4 ASIA PACIFIC
    • FIGURE 40 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET SNAPSHOT
    • TABLE 248 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 249 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 250 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 251 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 252 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 253 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021-2028 (USD MILLION)
    • TABLE 254 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 255 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 256 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 257 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 258 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 259 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 260 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021-2028 (USD MILLION)
    • TABLE 261 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.1 JAPAN
      • 12.4.1.1 Presence of large geriatric population to boost growth
    • TABLE 262 JAPAN: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 263 JAPAN: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 264 JAPAN: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 265 JAPAN: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 266 JAPAN: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 267 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 268 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 269 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 270 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 271 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.2 CHINA
      • 12.4.2.1 Increasing prevalence of food allergies and anaphylaxis to drive growth
    • TABLE 272 CHINA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 273 CHINA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 274 CHINA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 275 CHINA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 276 CHINA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 277 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 278 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 279 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 280 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 281 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.3 INDIA
      • 12.4.3.1 Increasing burden of diabetes and CVD to drive growth
    • TABLE 282 INDIA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 283 INDIA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 284 INDIA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 285 INDIA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 286 INDIA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 287 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 288 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 289 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 290 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 291 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.4 SOUTH KOREA
      • 12.4.4.1 Regulatory approvals for autoinjectors to drive growth
    • TABLE 292 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 293 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 294 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 295 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 296 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 297 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 298 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 299 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 300 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 301 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.5 REST OF ASIA PACIFIC
    • TABLE 302 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 303 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 304 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 305 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 306 ROAPAC: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 307 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 308 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 309 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 310 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 311 ROAPAC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.4.6 ASIA PACIFIC: RECESSION IMPACT
  • 12.5 LATIN AMERICA
    • 12.5.1 RISING GERIATRIC POPULATION TO SUPPORT GROWTH
    • TABLE 312 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 313 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 314 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 315 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 316 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021-2028 (USD MILLION)
    • TABLE 317 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 318 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 319 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 320 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 321 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 322 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021-2028 (USD MILLION)
    • TABLE 323 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.5.2 LATIN AMERICA: RECESSION IMPACT
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 FAVORABLE REFORMS IN AFRICA AND MIDDLE EASTERN COUNTRIES TO DRIVE GROWTH
    • TABLE 324 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 325 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 326 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 327 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 328 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2021-2028 (USD MILLION)
    • TABLE 329 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 330 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2021-2028 (USD MILLION)
    • TABLE 331 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 332 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 333 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2021-2028 (USD MILLION)
    • TABLE 334 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2021-2028 (USD MILLION)
    • TABLE 335 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 12.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • FIGURE 41 AUTOINJECTOR DEVICES AND FINISHED FORMULATIONS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
  • 13.3 REVENUE SHARE ANALYSIS FOR AUTOINJECTOR DEVICES MARKET
    • FIGURE 42 AUTOINJECTOR DEVICES MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2020-2022
  • 13.4 REVENUE SHARE ANALYSIS FOR AUTOINJECTOR FINISHED FORMULATIONS MARKET
    • FIGURE 43 AUTOINJECTOR FINISHED FORMULATIONS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2020-2022
  • 13.5 MARKET SHARE ANALYSIS FOR AUTOINJECTOR DEVICES MARKET
    • FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR DEVICES MARKET, 2022
    • TABLE 336 AUTOINJECTOR DEVICES MARKET: DEGREE OF COMPETITION
  • 13.6 MARKET SHARE ANALYSIS FOR AUTOINJECTOR FINISHED FORMULATIONS MARKET
    • FIGURE 45 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR FINISHED FORMULATIONS MARKET, 2022
    • TABLE 337 AUTOINJECTOR FINISHED FORMULATIONS MARKET: DEGREE OF COMPETITION
  • 13.7 COMPANY EVALUATION MATRIX FOR KEY PLAYERS
    • FIGURE 46 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
    • 13.7.1 STARS
    • 13.7.2 EMERGING LEADERS
    • 13.7.3 PERVASIVE PLAYERS
    • 13.7.4 PARTICIPANTS
  • 13.8 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
    • 13.8.1 PRODUCT FOOTPRINT OF COMPANIES (25 COMPANIES)
    • TABLE 338 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN AUTOINJECTORS MARKET
    • 13.8.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
    • TABLE 339 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN AUTOINJECTORS MARKET
  • 13.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES
    • FIGURE 47 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022
    • 13.9.1 PROGRESSIVE COMPANIES
    • 13.9.2 STARTING BLOCKS
    • 13.9.3 RESPONSIVE COMPANIES
    • 13.9.4 DYNAMIC COMPANIES
  • 13.10 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
    • TABLE 340 AUTOINJECTORS MARKET: LIST OF KEY STARTUP/SME PLAYERS
    • TABLE 341 AUTOINJECTORS MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
  • 13.11 COMPETITIVE SCENARIO AND TRENDS
    • 13.11.1 PRODUCT LAUNCHES
    • TABLE 342 AUTOINJECTORS MARKET: PRODUCT LAUNCHES, JANUARY 2020-APRIL 2023
    • 13.11.2 DEALS
    • TABLE 343 AUTOINJECTORS MARKET: DEALS, JANUARY 2020-APRIL 2023
    • 13.11.3 OTHER DEVELOPMENTS
    • TABLE 344 AUTOINJECTORS MARKET: OTHER DEVELOPMENTS, JANUARY 2020-APRIL 2023
    • 13.11.4 DEVICE PARTNERS FOR AUTOINJECTOR FINISHED FORMULATIONS
    • TABLE 345 DEVICE PARTNERS FOR AUTOINJECTOR FINISHED FORMULATIONS
    • 13.11.5 DEVICES FOR LARGE-VOLUME FORMULATIONS
    • TABLE 346 AUTOINJECTORS MARKET: DEVICES FOR LARGE-VOLUME FORMULATIONS
    • 13.11.6 DEVICES FOR HIGHLY VISCOUS FORMULATIONS
    • TABLE 347 AUTOINJECTORS MARKET: DEVICES FOR HIGHLY VISCOUS FORMULATIONS
    • TABLE 348 FORMULATIONS AND DEVICE TECHNOLOGIES ENABLING SUBCUTANEOUS DELIVERY OF HIGH-DOSE BIOLOGICS
    • 13.11.7 INSIGHTS ON FUTURE AREAS OF FOCUS IN AUTOINJECTORS MARKET

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS: DEVICES
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 14.1.1 BECTON, DICKINSON AND COMPANY (BD)
    • TABLE 349 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
    • FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
    • TABLE 350 BECTON, DICKINSON AND COMPANY: PRODUCT OFFERINGS
    • TABLE 351 BECTON, DICKINSON AND COMPANY: DEALS
    • TABLE 352 BECTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS
    • 14.1.2 YPSOMED HOLDING AG
    • TABLE 353 YPSOMED HOLDING AG: COMPANY OVERVIEW
    • FIGURE 49 YPSOMED HOLDING AG: COMPANY SNAPSHOT
    • TABLE 354 YPSOMED HOLDING AG: PRODUCT OFFERINGS
    • TABLE 355 YPSOMED HOLDING AG: PRODUCT LAUNCHES
    • TABLE 356 YPSOMED HOLDING AG: DEALS
    • 14.1.3 SHL MEDICAL
    • TABLE 357 SHL MEDICAL: COMPANY OVERVIEW
    • TABLE 358 SHL MEDICAL: PRODUCT OFFERINGS
    • TABLE 359 SHL MEDICAL: DEALS
    • TABLE 360 SHL MEDICAL: OTHER DEVELOPMENTS
    • 14.1.4 WEST PHARMACEUTICAL SERVICES, INC.
    • TABLE 361 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW
    • FIGURE 50 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 362 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCT OFFERINGS
    • TABLE 363 WEST PHARMACEUTICAL SERVICES, INC.: OTHER DEVELOPMENTS
    • 14.1.5 RECIPHARM AB
    • TABLE 364 RECIPHARM AB: COMPANY OVERVIEW
    • TABLE 365 RECIPHARM AB: PRODUCT OFFERINGS
    • TABLE 366 RECIPHARM AB: DEALS
    • 14.1.6 HASELMEIER GMBH
    • TABLE 367 HASELMEIER GMBH: COMPANY OVERVIEW
    • TABLE 368 HASELMEIER GMBH: PRODUCT OFFERINGS
    • TABLE 369 HASELMEIER GMBH: DEALS
    • TABLE 370 HASELMEIER GMBH: PRODUCT LAUNCHES
    • 14.1.7 OWEN MUMFORD LTD.
    • TABLE 371 OWEN MUMFORD LTD.: COMPANY OVERVIEW
    • TABLE 372 OWEN MUMFORD LTD.: PRODUCT OFFERINGS
    • TABLE 373 OWEN MUMFORD LTD.: PRODUCT LAUNCHES
    • TABLE 374 OWEN MUMFORD LTD.: DEALS
    • TABLE 375 OWEN MUMFORD LTD.: OTHER DEVELOPMENTS
    • 14.1.8 GERRESHEIMER AG
    • TABLE 376 GERRESHEIMER AG: COMPANY OVERVIEW
    • FIGURE 51 GERRESHEIMER AG: COMPANY SNAPSHOT (2022)
    • TABLE 377 GERRESHEIMER AG: PRODUCT OFFERINGS
    • TABLE 378 GERRESHEIMER AG: DEALS
    • 14.1.9 PHILLIPS-MEDISIZE, LLC
    • TABLE 379 PHILIPS-MEDISIZE, LLC: COMPANY OVERVIEW
    • TABLE 380 PHILIPS MEDISIZE, LLC: PRODUCT OFFERINGS
    • TABLE 381 PHILIPS MEDISIZE, LLC: PRODUCT LAUNCHES
    • TABLE 382 PHILIPS-MEDISIZE, LLC: OTHER DEVELOPMENTS
    • 14.1.10 OVAL MEDICAL TECHNOLOGIES LTD. (PART OF SMC LTD.)
    • TABLE 383 OVAL MEDICAL TECHNOLOGIES LTD.: COMPANY OVERVIEW
    • TABLE 384 OVAL MEDICAL TECHNOLOGIES LTD.: PRODUCT OFFERINGS
    • 14.1.11 KALEO, INC.
    • TABLE 385 KALEO, INC.: COMPANY OVERVIEW
    • TABLE 386 KALEO, INC.: PRODUCT OFFERINGS
    • 14.1.12 SOLTEAM INCORPORATION CO., LTD.
    • TABLE 387 SOLTEAM INCORPORATION CO., LTD.: COMPANY OVERVIEW
    • TABLE 388 SOLTEAM INCORPORATION CO., LTD.: PRODUCT OFFERINGS
    • 14.1.13 ELCAM DRUG DELIVERY DEVICES (E3D)
    • 14.1.14 CROSSJECT
    • TABLE 391 CROSSJECT: COMPANY OVERVIEW
    • TABLE 392 CROSSJECT: PRODUCT OFFERINGS
    • 14.1.15 JOHNSON MEDTECH, LLC. (PART OF JOHNSON ELECTRIC HOLDINGS LTD.)
    • TABLE 393 JOHNSON MEDTECH, LLC.: COMPANY OVERVIEW
    • TABLE 394 JOHNSON MEDTECH, LLC: PRODUCT OFFERINGS
    • 14.1.16 ANTARES PHARMA, INC. (PART OF HALOZYME, INC.)
    • TABLE 395 ANTARES PHARMA, INC.: COMPANY OVERVIEW
    • FIGURE 52 ANTARES PHARMA, INC.: COMPANY SNAPSHOT
    • TABLE 396 ANTARES PHARMA, INC.: PRODUCT OFFERINGS
    • TABLE 397 ANTARES PHARMA, INC.: DEALS
    • 14.1.17 JABIL, INC.
    • TABLE 398 JABIL, INC.: COMPANY OVERVIEW
    • TABLE 399 JABIL INC.: PRODUCT OFFERINGS
    • 14.1.18 CONGRUENCE MEDICAL SOLUTIONS LLC
    • TABLE 400 CONGRUENCE MEDICAL SOLUTIONS LLC: COMPANY OVERVIEW
    • TABLE 401 CONGRUENCE MEDICAL SOLUTIONS LLC: PRODUCT OFFERINGS
  • 14.2 KEY PLAYERS: FINISHED FORMULATIONS
    • 14.2.1 ABBVIE INC.
    • TABLE 402 ABBVIE INC.: COMPANY OVERVIEW
    • FIGURE 53 ABBVIE INC.: COMPANY SNAPSHOT
    • TABLE 403 ABBVIE INC.: PRODUCT OFFERINGS
    • TABLE 404 ABBVIE INC.: PRODUCT LAUNCHES
    • TABLE 405 ABBVIE INC.: OTHER DEVELOPMENTS
    • 14.2.2 AMGEN INC.
    • TABLE 406 AMGEN INC.: COMPANY OVERVIEW
    • FIGURE 54 AMGEN INC.: COMPANY SNAPSHOT
    • TABLE 407 AMGEN INC.: PRODUCT OFFERINGS
    • TABLE 408 AMGEN INC.: PRODUCT LAUNCHES
    • 14.2.3 ELI LILLY AND COMPANY
    • TABLE 409 ELI LILY AND COMPANY: COMPANY OVERVIEW
    • FIGURE 55 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
    • TABLE 410 ELI LILY AND COMPANY: PRODUCT OFFERINGS
    • TABLE 411 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS
    • 14.2.4 NOVARTIS AG
    • TABLE 412 NOVARTIS AG: COMPANY OVERVIEW
    • FIGURE 56 NOVARTIS AG: COMPANY SNAPSHOT
    • TABLE 413 NOVARTIS AG: PRODUCT OFFERINGS
    • TABLE 414 NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS
    • 14.2.5 MERCK KGAA
    • TABLE 415 MERCK KGAA: COMPANY OVERVIEW
    • FIGURE 57 MERCK KGAA: COMPANY SNAPSHOT
    • TABLE 416 MERCK KGAA: PRODUCT OFFERINGS
    • 14.2.6 VIATRIS INC. (FORMERLY MYLAN INC.)
    • TABLE 417 VIATRIS INC.: COMPANY OVERVIEW
    • FIGURE 58 VIATRIS INC.: COMPANY SNAPSHOT
    • TABLE 418 VIATRIS INC.: PRODUCT OFFERINGS
    • 14.2.7 BIOGEN
    • TABLE 419 BIOGEN: COMPANY OVERVIEW
    • FIGURE 59 BIOGEN: COMPANY SNAPSHOT
    • TABLE 420 BIOGEN: PRODUCT OFFERINGS
    • TABLE 421 BIOGEN: OTHER DEVELOPMENTS
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS